Optibrium, MSD Enter Cheminformatics Collaboration
Optibrium has entered into a cheminformatics collaboration with MSD (known as Merck & Co. in the United States).
Drug discovery software developer, Optibrium, has entered into a collaboration with MSD (known as Merck & Co. in the United States) for the integration of Optibrium’s software into MSD’s drug discovery infrastructure.
According to a Nov. 10, 2020 press release, the agreement covers the integration of Optibrium’s StarDrop software as a central component of MSD’s cheminformatics infrastructure. The resultant combination of Optibrium’s software with MSD’s in-house capabilities is expected to improve cycle times, efficiency, and productivity of drug discovery.
“We are delighted to enter this collaboration to contribute to MSD’s world-leading cheminformatics infrastructure,” said Dr. Matthew Segall, Optibrium’s CEO, in the press release. “We look forward to working together to advance new tools based around StarDrop to further refine our compound design platform.”
Source: Optibrium
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
